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ABSTRACT 
Predicting the absorption, distribution, metabolism and elimination (ADME) profile of drug candidates before their synthesis, in the early stage 
of drug discovery, could help in selecting candidates with the less critical ADME profile. In vivo ADME assessment is found to be costly, time 
consuming and involve the lives of animals, so the in vitro ADME analysis is better, cheaper and provides accurate results quickly. TUG-891 is a 
GPR-120 inhibitor under clinical trials. The aim of the present study is to predict the in vitro ADME studies of TUG-891, to know the expected 
outcome of the clinical trials and finding the correlation between the in vivo and in vitro results along with the improvisation in the structure of 
the TUG-891, so that the biological activity remains unaffected, but reduces the unwanted ADME effects. The 2D and 3D structures of TUG-891 
were drawn on chemdraw 3D-Ultra version 8.0 by minimizing the energy using MM2 and MOPAC setting the minimum RMS gradient to 0.01. 
The structure was imported, the structure smiley was entered and the Swiss ADME drug design study was run. The bioavailability radar 
showed that the colored zone is the suitable physicochemical space for oral bioavailability where the following properties were taken into 
consideration as flexibility, lipophilicity, saturation, size, polarity and solubility. The pharmacokinetic properties were studied using the boiled 
egg model allows for intuitive evaluation of passive gastrointestinal absorption and brain penetration in function of the position of the 
molecules in the WLOGP-versus-TPSA referential. The white region is for high probability of passive absorption by the gastrointestinal tract 
and the yellow region that is yolk, is for high probability of brain penetration. Yolk and white areas are not mutually exclusive. Through the 
study conducted it could be concluded that the aqueous solubility of the compound should be increased along with the fraction of sp 3 
hybridized carbon atoms. The molecule should not be the inhibitor of metabolizing enzymes and so further modifications need to be done on 
the lead structure. 
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INTRODUCTION 
Drug development involves the assessment of efficacy and 
toxicity of the new drug candidates and includes generating 
a hypothesis of the target receptor for a particular disorder 
and screening the in vitro and/or in vivo biological activities 
of the new drug candidates. A critical piece in drug discovery 
and development is conducting DMPK (drug metabolism and 
pharmacokinetics) studies, often referred to as ADMET 
(absorption, distribution, metabolism, elimination and 
toxicity) studies. The initiation of early absorption, 
distribution, metabolism and excretion (ADME) screening 
has dramatically decreased the proportion of compounds 
failing in clinical trials. The main aim of preclinical ADME is 
to eliminate weak drug candidates in the early stages of drug 
development, which allow resources to be focused on 
potential drug candidates.1 Regulatory authorities have 
relied on in vivo testing to predict the behavior of new 
molecules in the human body since the 1950s. 
Bioavailability, tissue distribution, pharmacokinetics, 
metabolism and toxicity are typically assessed in one rodent 
and one non-rodent species (dog or non-human primate) 
prior to administering a drug to a human to evaluate 
pharmacokinetics and exposure in a clinical trial, phase 1. 
The standard required methodology for bio-distribution 
assessment uses radioactively labeled compounds. This is 
time- and resource-intensive both in terms of synthesizing 
sufficient amounts of radioactively labeled compound and of 
performing the animal experiments.2 Therefore, these assays 
are implemented rather late in the preclinical development 
process when more resources are released to study the few 
molecules that have advanced to that stage. With advances 
in cell and molecular biology, high-throughput screening and 
miniaturization technologies in the 1990s, as well as stem 
cell-derived models at the beginning of this century, early in 
vitro ADME studies have been developed to predict in vivo 
animal and human results at a level of speed and cost 
effectiveness appropriate for the early discovery stage.3 The 
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preclinical studies for drug screening involve the use of 
animals which is very time consuming and expensive and at 
times leads to suffering of the used organism. This has 
forced the researchers to find ways to not only decrease the 
time involved in drug screening procedures but also 
decrease the number of animals used and also increase the 
humane care of animals. To fulfill this goal a number of 
new in vitro techniques have been devised which are called 
‘Alternatives’ or ‘Substitutes’ for use of animals in research 
involving drugs. The advantages of these alternatives include 
the decrease in the number of animals used, ability to obtain 
the results quickly, reduction in the costs and flexibility to 
control the variables of the experiment.2 The progress of 
ADME profiling has decreased the proportion of drug 
candidates failing in clinical trials for ADME reasons and 
providing important early input into safety and toxicity 
prediction of drug candidates.  
Swiss ADME web tool is freely available software used to 
predict the physicochemical properties, absorption, 
distribution, metabolism, elimination and pharmacokinetic 
properties of molecules, which are key endeavors to further, 
go for the clinical trials. It takes into account six 
physicochemical properties, which are most important like 
flexibility, lipophilicity, saturation, size, polarity and 
solubility.4  
Drug likeliness parameters can be studied by using few rules 
which were set by some pharmaceutical companies setting 
the relationship between the pharmacokinetic properties 
and biological activities which should be followed for having 
in vivo activity. Lipinski rule of five was given by Pfizer 
stating that there should be less than 500 dalton molecular 
weight, the hydrogen bond acceptor should be not more 
than 10, the hydrogen bond donor should be more than 5, 
log P value should be not more than 5 and the biological 
transporters should not be a part of drug. Ghose rule was 
given by Amgen which stated that log P value should be from 
-0.4 to +5.6, molar refractivity should be between 40-130, 
the molecular weight should be between 180-480 and the 
number of atoms should be 20-70, including hydrogen bond 
donor and hydrogen bond acceptor. The Egan rule was given 
by Pharmacia Company for the prediction of human 
intestinal absorption stating the log P value should not be 
more than 5.88 and topological polar surface area should not 
be more than 131.6. Some drugs like steroids the molecular 
weight should be more than 500 D, 10 or fewer rotatable 
bonds should be there, polar surface area should not be 
more than 140 Aᵒ are orally active stated by Verber, given by 
GSK pharmaceuticals. Muegge rule was given by Bayer 
Pharmaceuticals, stated the parameters as, molecular weight 
200-600 D, log P between -2 to +5, topological surface area 
not more than 150, number of rings not more than 7, 
number of carbon atoms not less than 4, number of 
heteroatoms more than 1, number of rotatable bonds not 
more than 15, hydrogen bond donor atoms not more than 5 
and hydrogen bond acceptor atoms should be more than 10. 
Abbott bioavailability F should not be more than 10%.5 
For having a good biological activity, a drug should have 
sufficient lipophilic character so that it can cross the cell 
membrane. The lipophilicity parameter can be calculated by 
using several methods. ilogP stands for in-house physics 
based method relying on free energies of solvation in n-
octanol and water calculated by generalized born and 
solvent accessible surface area model. The XlogP3 is an 
atomistic method including corrective factors and 
knowledge based library calculated by XlogP program. 
WlogP is an atomistic method based on fragmental system. 
MlogP is topological method relying on a linear relationship 
with 13 molecular descriptors. SILICOS-IT logP is a hybrid 
method relying on fragment and topological descriptors. 
Consensus logP is arithmetic mean of all five predictions of 
lipophilic character.5 
A drug should have good aqueous solubility for oral 
bioavailability and absorption. The water solubility is 
predicted by three methods namely ESOL, (ALI) logS and 
(SILICOS-IT) logS. ESOL stands for estimating aqueous 
solubility directly from molecular structure directly from 
molecular structure followed by molecular weight, 
proportion of heavy atoms in aromatic system and number 
of rotatable bonds. The model performed consistently well 
across 3 validation sets predicting solubility within a factor 
of 5-8. Log S (Ali) determines the in silico prediction of 
aqueous solubility incorporating the effect of topological 
polar surface area. Log (SILICOS-IT) determines the negative 
logarithm of water solubility of a compound by fragmental 
method. The log S scale value ranges between -10 
(insoluble), -6 (poorly soluble), -4 (soluble), -2 (very 
soluble) and 0 (highly soluble).4,5 
Pharmacokinetic parameters include gastrointestinal 
absorption, blood-brain barrier permeation, P-gp substrate, 
CYP 1A2 inhibitor, CYP2C19 inhibitor, CYP2C9 inhibitor, 
CYP2D6 inhibitor, CYP3A4 inhibitor and Log Kp (skin 
permeation). One model is a multiple linear regression, 
which aims at predicting the skin permeability coefficient 
(Kp). It is adapted from Potts and Guy, who found Kp linearly 
correlated with molecular size and lipophilicity (R2=0.67). 
The more negative the log Kp (with Kp in cm/s), the less skin 
permeant is the molecule. The predictions for passive 
human gastrointestinal absorption and blood-brain barrier 
permeation both consist in the readout of the BOILED-Egg 
model 17. Brain or Intestinal Estimated Permeation method 
(BOILED egg) is proposed as an accurate predictive model 
that works by computing the lipophilicity and polarity of 
small molecules. Permeability glycoprotein (P-gp) substrate 
is key to appraise active efflux through biological membrane. 
It protects CNS from xenobiotics and is overexpressed in 
tumor cells. 50-90% molecules are substrates of 5 major 
isoforms CYP 1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4. 
Inhibition of these isoenzyme is certainly one major cause of 
pharmacokinetics related drug-drug interactions leading to 
toxic ADME due to accumulation of drug/ metabolites.6 
Pan assay interference compounds (PAINS) are chemical 
compounds that often give false positive results in high 
throughput screens. It tends to react non-specifically with 
numerous biological targets rather than specifically affecting 
one desired target. Common PAINS include curcumin, phenl 
sulfonamides, isothiazolones, quinanones, catechols etc. 
Synthetic accessibility score ranges from 1 (very easy) to 10 
(very difficult).  
TUG-891 is a GPR-120 inhibitor which is under clinical trials. 
The aim of the present study is to predict the in vitro ADME 
studies of TUG-891, to know the expected outcome of the 
clinical trials and finding the correlation between the in vivo 
and in vitro results along with the improvisation in the 
structure of the TUG-891, so that the biological activity 
remains unaffected, but reduces the unwanted ADME effects.  
MATERIALS AND METHOD 
Swiss ADME is a free web tool to evaluate pharmacokinetics, 
drug-likeness and medicinal chemistry friendliness of small 
molecules. Compared to the state-of-the art of free web-
based tools for ADME and pharmacokinetics e.g. pk-CSM4  
and admetSAR5 and apart from unique access to proficient 
methods e.g. iLOGP7 or the BOILED-Egg,8 strong points of 
Swiss ADME are non-exhaustively: different input methods, 
computation for multiple molecules and the possibility to 
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display, save and share results per individual molecule or 
through global intuitive and interactive graphs. Finally, 
Swiss ADME is integrated in the Swiss Drug Design 
workspace.9 
The 2D structure of TUG-891 was drawn on chemdraw, 2D 
and 3D structures were drawn on chemdraw 3D-Ultra 
version 8.0 by minimizing the energy using MM2 and 
MOPAC setting the minimum RMS gradient to 0.01. The 
structure was imported and the structure smiley was 
entered. The Swiss ADME drug design study was run and the 
reading were noted down. 
RESULT AND DISCUSSION 
The bioavailability radar (Figure 1) showed that the colored 
zone is the suitable physicochemical space for oral 
bioavailability where the following properties were taken 
into consideration as flexibility, lipophilicity, saturation, size, 
polarity and solubility. The lipophilicity of the compound log 
P can range from -0.7 to +5.0. The molecular weight can 
range from 150 g/mol to 500 g/mol. The topological polar 
surface area ranges from 20-130 Aᵒ2. The insolubility studied 
using log S (ESOL) ranges between 0 to 6. The number of 
rotatable bonds should be between 0-9 and the unsaturation 
fraction ranges from 0.25 to 1.0 indicating the fraction of 
carbon atoms in the sp3 hybridization should not be less 
than 0.25.  
The physicochemical properties states that the molecular 
formula of the compound is C23H21FO3. The molecular weight 
was 364.41 g/mol. The number of heavy atoms is 27 and 
number of aromatic heavy atoms was 18. The fraction of 
carbon atoms in the sp3 hybridization was 0.17. The 
numbers of rotatable bonds were 7, the numbers of 
hydrogen bond acceptors were 4 and the number of 
hydrogen bond donor was 1. The molar refractivity was 
104.13 and the topological polar surface area was found to 
be 46.53 Aᵒ2.  
The log Po/w (ilog P) is 3.00, the log Po/w (Xlog P3) is 5.24, the 
log Po/w (Wlog P) is 5.67, the log Po/w (MlogP) is 4.78, the log 
Po/w (SILICOS-IT) is 6.12 and the consensus log Po/w is 4.96 
respectively. From the log P values overall it can be 
concluded that the compound is having good lipophilic 
character. 
The water solubility of the compound was studied using log 
S (ESOL) value as -5.43 depicting the compound belongs to 
moderately water soluble class. 
 
Figure 1:  The bioavailability radar of TUG-891 using 
Swiss ADME predictor. 
The pharmacokinetic properties were studied using the 
boiled egg model (7) allows for intuitive evaluation of 
passive gastrointestinal absorption (HIA) and brain 
penetration (BBB) in function of the position of the 
molecules in the WLOGP-versus-TPSA referential (Figure 2). 
The white region is for high probability of passive 
absorption by the gastrointestinal tract, and the yellow 
region (yolk) is for high probability of brain penetration. 
Yolk and white areas are not mutually exclusive.  
 
 
Figure 2: Molecule falling in egg’s yolk is predicting the molecule is able to penetrate through the blood brain barrier. 
 
The molecule TUG 891 is showing high gastrointestinal 
absorption and easily permeate blood brain barrier. It is not 
a P-gp substrate means there would not be an issue in the 
excretion of drug. P-glycoprotein plays a significant role in 
drug absorption and disposition. Because of its localization, 
P-glycoprotein appears to have a greater impact on limiting 
cellular uptake of drugs from blood circulation into brain and 
from intestinal lumen into epithelial cells than on enhancing 
the excretion of drugs out of hepatocytes and renal tubules 
into the adjacent luminal space. It is an inhibitor of 
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isoenzyme CYP2C19 and CYP2D6 which means there might 
be the chances of accumulation or drug-drug interaction 
resulting in toxicity.  
Drug likeness parameter is high as it is following Lipinski, 
verber, egan rule with the bioavailability score of 0.56. Swiss 
ADME Synthetic Accessibility (SA) Score is based primarily 
on the assumption that the frequency of molecular fragments 
in ‘really’ obtainable molecules correlates with the ease of 
synthesis. The fragmental contribution to SA should be 
favorable for frequent chemical moieties and unfavorable for 
rare moieties. The synthetic accessibility score was found to 
be 2.78 which means it would not be tough to synthesize the 
molecule. There is no alert for PAINS indicating the 
compound is quite specific in nature. 
CONCLUSION 
The traditional clinical trial approaches needs a lot of time 
and money investment after which it might conclude that the 
molecule fails, so in order to reduce or modify the lead 
structure it is important to go for the in vitro studies rather 
than blindly following monopoly and rushing for the animal 
studies. Swiss ADME web tool enables the computation of 
key physicochemical, pharmacokinetic, drug-like and related 
parameters for one or multiple molecules. Through the study 
conducted it could be concluded that the aqueous solubility 
of the compound should be increased along with the fraction 
of sp3 hybridized carbon atoms. The molecule should not be 
the inhibitor of metabolizing enzymes and so further 
modifications need to be done on the lead structure. 
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